{
  "docId": "019de073-98a7-740c-b2bf-3eb3f25491f5",
  "docSlug": "adb5c4514a6016378ffb63c7d4422971",
  "documentTitle": "TCR2 Therapeutics | Results Presentation Deck | 34 slides",
  "authorId": "tcr2-therapeutics",
  "authorName": "TCR2 Therapeutics",
  "documentKindSlug": "regulatory-filing",
  "documentKindLabel": "Regulatory filing",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 34,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "key_takeaways",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 25,
  "notes": "Waterfall plot shows individual patient responses; ORR, PFS, and OS metrics provided.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-98a7-740c-b2bf-3eb3f25491f5/11",
  "deckHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5",
  "deckJsonHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5.json",
  "deckAnchorHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.5,
        "x": 0.45,
        "y": 0.2
      },
      "kind": "chart",
      "text": "Waterfall plot showing change in target lesions from baseline for individual patients.",
      "attrs": null,
      "subkind": "waterfall",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ba323b9a-b75d-41b9-9260-a4a06015c9d3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.4,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "list",
      "text": "MPM Highlights: 21/22 patients experienced tumor regression; 5/22 partial responses by target lesion; 4/22 RECIST partial responses; 1 complete metabolic response.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9418aeab-7974-466f-ab31-99babc99bf33",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.3,
        "x": 0.05,
        "y": 0.55
      },
      "kind": "list",
      "text": "Efficacy Data: ORR: 21% (gavo-cel + LD); PFS: 5.6 months; OS: 11.2 months.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c908c7fa-b07c-419e-83a1-829183c9007e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.45,
        "y": 0.85
      },
      "kind": "source-note",
      "text": "Tumor volume decrease based on best response assessed. Data Cutoff - September 9, 2022.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cd110a8c-54e8-463c-ad58-c0849658b50a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Phase 1 Data Support a Path Forward as Mesothelioma Leader",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ea3485dc-6636-48e8-b5f8-6f7d50fdbdb4",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Waterfall chart",
      "slug": "waterfall-chart",
      "agent": null,
      "layer": "slide",
      "matchId": "65852e22-307a-4557-bc51-ea91628bd2a3",
      "evidence": "chart/waterfall: Waterfall plot showing change in target lesions from baseline for individual patients.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 18,
      "from": 8,
      "beatId": "fd7bc9b8-ed02-40c1-b1d1-66cb54ef449d",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document presents TRuC-T cell therapy as a solution, showcasing Phase 1 trial results.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 18,
      "from": 8,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "0a2012e0-6a06-4e15-803c-e8ae832be1d6",
      "evidence": "The document presents TRuC-T cell therapy as a solution, showcasing Phase 1 trial results.",
      "position": 1,
      "objective": "How can TRuC-T cell therapy address the needs of patients with solid tumors?",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.7,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}